Recursion Pharmaceuticals Inc (RXRX) Implied Volatility Current

Tracking RXRX implied volatility helps you identify when options premiums on Recursion Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Recursion Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when RXRX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Recursion Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For RXRX, tracking metrics like RXRX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on RXRX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.

The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where RXRX implied volatility sits today versus where it has been. Our scanner ranks Recursion Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in RXRX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Recursion Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.